Unlock instant, AI-driven research and patent intelligence for your innovation.

Formulations for the treatment of mucosal lesions

A mucosal injury and active agent technology, applied in the field of preparations for the treatment of mucosal injury, can solve the problems of no synergy, no specific combination of reagents, etc.

Active Publication Date: 2018-05-08
拉曼梅塔
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The publication Drugs of the Future, 2008, 33(4), pp. 329-346 describes the activities of pomegranate, turmeric or ginger respectively: the literature deals with these plants and their active components (antioxidants, anti-inflammatory agents, antibacterial agents, anticancer agents, antimutagenic agents, etc.) without any suggestion or teaching on how to optimize their activity; the document does not suggest any specific combination of these agents nor their possible synergy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0018] According to another preferred embodiment, the formulation contains three extracts (referred to as dry extracts) at the following weight intervals per dosage unit:

[0019] Turmeric Extract: ................................20 to 100mg,

[0020] Pomegranate extract (approximately 40% ellagic acid derivative) ... 10 to 60 mg

[0021] Ginger extract (about 35% gingerol): ..........2 to 20mg

[0022] According to a more preferred embodiment, the content of each dosage unit is (referring to dry extract):

[0023] Turmeric Extract: ................................. 50mg,

[0024] Pomegranate extract (about 40% ellagic acid derivative)...20mg

[0025] Ginger extract (approximately 35% gingerol): ..........10mg

[0026]A further preferred embodiment relates to the topical gel formulation described in Example 1 of the present application or the orodispersible mucoadhesive tablet described in Example 2 of the present application, or the sustained release formulation tablet de...

Embodiment 1

[0037] Example 1 Topical Gel

[0038] Turmeric Alcohol Extract (Curcuma longa) or other kind...................500mg

[0039] Pomegranate Extract 40% Ellagic Acid Derivative .................120mg

[0040] Ginger lipophilic extract................................200mg

[0041] Hydroxyethyl Cellulose ................................. 3000mg

[0042] Polysorbate 80....................................3000mg

[0043] Methylparaben................................100mg

[0044] Propylene glycol .............................................. to 100000mg

Embodiment 2

[0045] Example 2 Orodispersible mucoadhesive tablet

[0046] Turmeric Alcohol Extract (Curcuma longa) or other kinds...................50mg,

[0047] Pomegranate Extract 40% Ellagic Acid Derivative ................. 20mg

[0048] Ginger lipophilic extract................................10mg

[0049] Sodium alginate................................200mg

[0050] Xylitol ............................................600mg

[0051] Ammonium glycyrrhizinate ................................. 10mg

[0052] Cyclamate................................................40mg

[0053] Polysorbate 80 ................................. 5mg

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to formulations containing a combination of extracts from Curcuma longa, Punica granatum and Zingiber officinale, useful for the treatment and prevention of mucosal lesions, in particular those caused by Herpes virus or Behcet's syndrome. The formulations are especially effective in reducing the incidence of mucosal lesions of the mouth, throat and genital area.

Description

Background technique [0001] Mucosal lesions are an important pathological symptom of many diseases and cause severe suffering to affected patients. Mucosal injury, especially of the oral cavity or throat, is the most disturbing symptom of Behçet syndrome and Herpes virus infection. [0002] Behçet syndrome, also known as Behcet's disease, is a rare disorder that causes inflammation of blood vessels in the body. Behcet's disease can include mouth sores, eye inflammatory rashes and lesions, and genital sores. Signs and symptoms vary from person to person and can come and go on their own. The exact cause of this syndrome is unknown, but it may be an autoimmune disorder of the body's immune system. Genetic and environmental factors may be responsible for Behçet syndrome. This pathology is very rare in Western countries, but has some distribution in the Middle East and Asia. Diagnosis of Behçet syndrome can take a long time because symptoms can come and go. For Behçet syndrome...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/9068A61K9/06A61P43/00A61P1/02A61P11/04A61P15/00A61P31/22A61P27/02A61P31/04A61P31/10A61P9/14A61P29/00A61P37/02
CPCA61K9/0056A61K9/006A61K9/06A61K36/185A61K36/9066A61K36/9068A61K2300/00A61P1/02
Inventor 拉曼·梅塔
Owner 拉曼梅塔